Featured Research

from universities, journals, and other organizations

New target for the fight against cancer as a result of excessive blood vessel formation

Date:
August 1, 2013
Source:
VIB (the Flanders Institute for Biotechnology)
Summary:
New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments is limited by resistance, poor efficiency and harmful side effects. Scientists reported that sugar metabolism (a process that we call glycolysis) also plays an essential role in the formation of new blood vessels.

New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments is limited by resistance, poor efficiency and harmful side effects. In the journal Cell, Peter Carmeliet (VIB-KU Leuven) and his team reported that sugar metabolism (a process that we call glycolysis) also plays an essential role in the formation of new blood vessels. These totally revolutionary insights open up many new therapeutic opportunities for the treatment of cancer and diseases as a result of excessive blood vessel formation.

Every growing cell in our body is provided with oxygen and nutrients via our blood vessels. Blood vessels are formed by endothelial cells which line the inside wall of the vessel. These cells require energy to be able to form new blood vessels. However, it was not known how these cells produced the required energy and it was never considered to inhibit the energy production process in order to block angiogenesis.

Under the guidance of Peter Carmeliet, a team consisting of Katrien De Bock, Maria Georgiadou and Sandra Schoors discovered that glycolysis is the most important mechanism for endothelial cells to supply energy for blood vessel formation. Peter Carmeliet and his team demonstrated that endothelial cells can be paralyzed by blocking glycolysis and consequently stop to form blood vessels. This is the first evidence that starvation of endothelial cells could offer new therapeutic opportunities for the treatment of excessive angiogenesis in diseases (like cancer).

Peter Carmeliet: "Our discovery opens up a whole new domain for inhibition of angiogenesis in various diseases such as cancer. Endothelial cells need nutrients and energy for growth and if you take away their energy, you can prevent them from forming new blood vessels."


Story Source:

The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology). Note: Materials may be edited for content and length.


Journal Reference:

  1. Katrien De Bock, Maria Georgiadou, Sandra Schoors, Anna Kuchnio, Brian W. Wong, Anna Rita Cantelmo, Annelies Quaegebeur, Bart Ghesquière, Sandra Cauwenberghs, Guy Eelen, Li-Kun Phng, Inge Betz, Bieke Tembuyser, Katleen Brepoels, Jonathan Welti, Ilse Geudens, Inmaculada Segura, Bert Cruys, Franscesco Bifari, Ilaria Decimo, Raquel Blanco, Sabine Wyns, Jeroen Vangindertael, Susana Rocha, Russel T. Collins, Sebastian Munck, Dirk Daelemans, Hiromi Imamura, Roland Devlieger, Mark Rider, Paul P. Van Veldhoven, Frans Schuit, Ramon Bartrons, Johan Hofkens, Peter Fraisl, Sucheta Telang, Ralph J. DeBerardinis, Luc Schoonjans, Stefan Vinckier, Jason Chesney, Holger Gerhardt, Mieke Dewerchin, Peter Carmeliet. Role of PFKFB3-Driven Glycolysis in Vessel Sprouting. Cell, 2013; 154 (3): 651 DOI: 10.1016/j.cell.2013.06.037

Cite This Page:

VIB (the Flanders Institute for Biotechnology). "New target for the fight against cancer as a result of excessive blood vessel formation." ScienceDaily. ScienceDaily, 1 August 2013. <www.sciencedaily.com/releases/2013/08/130801125606.htm>.
VIB (the Flanders Institute for Biotechnology). (2013, August 1). New target for the fight against cancer as a result of excessive blood vessel formation. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/08/130801125606.htm
VIB (the Flanders Institute for Biotechnology). "New target for the fight against cancer as a result of excessive blood vessel formation." ScienceDaily. www.sciencedaily.com/releases/2013/08/130801125606.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins